Prevention and Treatment of Chemotherapy-Induced Cardiotoxicity
References
- Siegel RL Miller KD Jemal A Cancer statistics, 2019 CA Cancer J Clin 2019 Jan 69 1 7 34
- Bloom MW Hamo CE Cardinale D Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging Circ Heart Fail 2016 Jan 9 1 e002661
- Henriksen PA Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention Heart 2018 Jun 104 12 971 7
- Tabár L Dean PB Chen TH The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening Cancer 2019 Feb 15 125 4 515 523
- Koutsoukis A Ntalianis A Repasos E Kastritis E Dimopoulos MA Paraskevaidis I Cardio-oncology: A Focus on Cardiotoxicity Eur Cardiol 2018 Aug 13 1 64 9
- Miller KD Siegel RL Lin CC Cancer treatment and survivorship statistics, 2016 CA Cancer J Clin 2016 Jul 66 4 271 89
- Suter TM Ewer MS Cancer drugs and the heart: importance and management Eur Heart J 2013 Apr 34 15 1102 11
- Cardinale D Biasillo G Cipolla CM Curing Cancer, Saving the Heart: A Challenge That Cardioncology Should Not Miss Curr Cardiol Rep 2016 Jun 18 6 51
- Zamorano JL Lancellotti P Rodriguez Muñoz D 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) Eur Heart J 2016 Sep 21 37 36 2768 801
- Yancy CW Jessup M Bozkurt B 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America J Card Fail 2017 Aug 23 8 628 51
- Cardinale D Colombo A Lamantia G Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy J Am Coll Cardiol 2010 Jan 19 55 3 213 20
- Cardinale D Colombo A Bacchiani G Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy Circulation 2015 Jun 2 131 22 1981 8
- Thavendiranathan P Poulin F Lim KD Plana JC Woo A Marwick TH Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review J Am Coll Cardiol 2014 Jul 1 63 25 Pt A 2751 68
- Liu J Banchs J Mousavi N Contemporary Role of Echocardiography for Clinical Decision Making in Patients During and After Cancer Therapy JACC Cardiovasc Imaging 2018 Aug 11 8 1122 31
- Negishi T Thavendiranathan P Negishi K Marwick TH SUCCOUR investigators Rationale and Design of the Strain Surveillance of Chemotherapy for Improving Cardiovascular Outcomes: The SUCCOUR Trial JACC Cardiovasc Imaging 2018 Aug 11 8 1098 1105
- Pituskin E Mackey J Koshman S Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): a Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity J Clin Oncol 2017 Mar 10 35 8 870 7
- Slamon DJ Leyland-Jones B Shak S Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overex-presses HER2 N Engl J Med 2001 Mar 15 344 11 783 92
- Cameron D Piccart-Gebhart MJ Gelber RD 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial Lancet 2017 Mar 25 389 10075 1195 205
- Goldhirsch A Gelber RD Piccart-Gebhart MJ Herceptin Adjuvant (HERA) Trial Study Team 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Lancet 2013 Sep 21 382 9897 1021 8
- Moja L Tagliabue L Balduzzi S Trastuzumab containing regimens for early breast cancer Cochrane Database Syst Rev 2012 Apr 18 4 CD006243
- Ewer MS Vooletich MT Durand JB Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment J Clin Oncol 2005 Nov 1 23 31 7820 6
- Fei HW Ali MT Tan TC Left Ventricular Global Longitudinal Strain in HER-2 + Breast Cancer Patients Treated with Anthracyclines and Trastuzumab Who Develop Cardiotoxicity Is Associated with Subsequent Recovery of Left Ventricular Ejection Fraction Echocardiography 2016 Apr 33 4 519 26
- Ohtani K Ide T Hiasa KI Cardioprotective effect of renin-angiotensin inhibitors and β-blockers in trastuzumab-related cardiotoxicity Clin Res Cardiol 2019 Oct 108 10 1128 1139
- Cameron D Brown J Dent R Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial Lancet Oncol 2013 Sep 14 10 933 42
- Chaar M Kamta J Ait-Oudhia S Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities Onco Targets Ther 2018 Sep 25 11 6227 37
- Plana JC Galderisi M Barac A Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging Eur Heart J Cardiovasc Imaging 2014 Oct 15 10 1063 93
- Ghatalia P Morgan CJ Je Y Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors Crit Rev Oncol Hematol 2015 May 94 2 228 37
- Sundararajan S Kumar A Poongkunran M Kannan A Vogelzang NJ Cardiovascular adverse effects of targeted antiangiogenic drugs: mechanisms and management Future Oncol 2016 12 8 1067 80
- Uraizee I Cheng S Moslehi J Reversible cardiomyopathy associated with sunitinib and sorafenib N Engl J Med 2011 Oct 27 365 17 1649 50
- Jain D Aronow W Cardiotoxicity of cancer chemotherapy in clinical practice Hosp Pract (1995) 2019 Feb 47 1 6 15
- Johnson DB Chandra S Sosman JA Immune Checkpoint Inhibitor Toxicity in 2018 JAMA 2018 Oct 23 320 16 1702 3
- Hu JR Florido R Lipson EJ Cardiovascular toxicities associated with immune checkpoint inhibitors Cardiovasc Res 2019 Apr 15 115 5 854 68
- Johnson DB Balko JM Compton ML Fulminant Myocarditis with Combination Immune Checkpoint Blockade N Engl J Med 2016 Nov 3 375 18 1749 55
- Mahmood SS Fradley MG Cohen JV Myocarditis in Patients Treated With Immune Checkpoint Inhibitors J Am Coll Cardiol 2018 Apr 24 71 16 1755 64
- Lyon AR Yousaf N Battisti NML Moslehi J Larkin J Immune checkpoint inhibitors and cardiovascular toxicity Lancet Oncol 2018 Sep 19 9 e447 e458
- Jones LW Liu Q Armstrong GT Exercise and risk of major cardiovascular events in adult survivors of childhood hodgkin lymphoma: a report from the childhood cancer survivor study J Clin Oncol 2014 Nov 10 32 32 3643 50
- Mishra SI Scherer RW Geigle PM Exercise interventions on health-related quality of life for cancer survivors Cochrane Database Syst Rev 2012 Aug 15 8 CD007566
- Lyu YL Kerrigan JE Lin CP Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane Cancer Res 2007 Sep 15 67 18 8839 46
- Swain SM Whaley FS Gerber MC Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer J Clin Oncol 1997 Apr 15 4 1318 32
- Kalay N Basar E Ozdogru I Protective effects of carvedilol against anthracycline-induced cardiomyopathy J Am Coll Cardiol 2006 Dec 5 48 11 2258 62
- Kaya MG Ozkan M Gunebakmaz O Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study Int J Cardiol 2013 Sep 1 167 5 2306 10
- Gulati G Heck SL Ree AH Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol Eur Heart J 2016 Jun 1 37 21 1671 80
-
Avila
MS
Ayub-Ferreira
SM
de Barros Wanderley
MR
Jr Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial J Am Coll Cardiol 2018 May 22 71 20 2281 90 - Cardinale D Colombo A Sandri M Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition Circulation 2006 Dec 5 114 23 2474 8
- Georgakopoulos P Roussou P Matsakas E Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up Am J Hematol 2010 Nov 85 11 894 6
- Bosch X Rovira M Sitges M Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies) J Am Coll Cardiol 2013 Jun 11 61 23 2355 62
- Guglin M Krischer J Tamura R Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer J Am Coll Cardiol 2019 Jun 11 73 22 2859 68
- Cardinale D Ciceri F Latini R ICOS-ONE Study Investigators Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial Eur J Cancer 2018 May 94 126 37
- Akpek M Ozdogru I Sahin O Protective effects of spironolactone against anthracycline-induced cardiomyopathy Eur J Heart Fail 2015 Jan 17 1 81 9
- Acar Z Kale A Turgut M Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy J Am Coll Cardiol 2011 Aug 23 58 9 988 9
- Seicean S Seicean A Plana JC Budd GT Marwick TH Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study J Am Coll Cardiol 2012 Dec 11 60 23 2384 90
- Calvillo-Argüelles O Abdel-Qadir H Michalowska M Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy Can J Cardiol 2019 Feb 35 2 153 159
DOI: https://doi.org/10.14797/mdcj-15-4-267 | Journal eISSN: 1947-6108
Language: English
Page range: 267 - 273
Published on: Oct 1, 2019
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
Keywords:
© 2019 Monica Samuel Avila, Suellen Rodrigues Rangel Siqueira, Silvia Moreira Ayub Ferreira, Edimar Alcides Bocchi, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.